In August 2011, the companies decided to suspend the pramlintide/metreleptin investigational combination therapy development.
The decision was based on a commercial re-assessment of the program, which had been in phase II development of a twice-a-day injection formulation.
Japan-based Takeda expects to carry on enhancing R&D activities in the area of obesity in addition to other main therapeutic aspects.